Article

Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis.

Department of Pathology, University of Geneva, Switzerland.
Journal of Clinical Investigation (Impact Factor: 13.77). 08/1995; 96(1):250-9. DOI: 10.1172/JCI118029
Source: PubMed

ABSTRACT The murine TNF-alpha gene was expressed under the control of the human surfactant protein SP-C promoter in transgenic mice. A number of the SP-C TNF-alpha mice died at birth or after a few weeks with very severe lung lesions. Surviving mice transmitted a pulmonary disease to their offspring, the severity and evolution of which was related to the level of TNF-alpha mRNA in the lung; TNF-alpha RNA was detected in alveolar epithelium, presumably in type II epithelial cells. In a longitudinal study of two independent mouse lines, pulmonary pathology, at 1-2 mo of age, consisted of a leukocytic alveolitis with a predominance of T lymphocytes. Leukocyte infiltration was associated with endothelial changes and increased levels of mRNA for the endothelial adhesion molecule VCAM-1. In the following months, alveolar spaces enlarged in association with thickening of the alveolar walls due to an accumulation of desmin-containing fibroblasts, collagen fibers, and lymphocytes. Alveolar surfaces were lined by regenerating type II epithelial cells, and alveolar spaces contained desquamating epithelial cells in places. Platelet trapping in the damaged alveolar capillaries was observed. Pulmonary pathology in the SP-C TNF-alpha mice bears a striking resemblance to human idiopathic pulmonary fibrosis, in which increased expression of TNF-alpha in type II epithelial cells has also been noted. These mice provide a valuable animal model for understanding the pathogenesis of pulmonary fibrosis and exploring possible therapeutic approaches.

0 Followers
 · 
79 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: PM and DM are often complicated by interstitial lung disease (ILD). In this study we aimed to evaluate various serum cytokines in patients with PM/DM with ILD so as to clarify the differences in pathophysiology between anti-melanoma differentiation-associated gene 5 antibody-associated ILD (anti-MDA5-ILD) and anti-aminoacyl tRNA synthetase antibody-associated ILD (anti-ARS-ILD).
    Rheumatology (Oxford, England) 06/2014; DOI:10.1093/rheumatology/keu258 · 4.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anti-tumor necrosis factor α therapeutics has represented the potential to alleviate pulmonary fibrosis. However, systemic administration of anti-tumor necrosis factor α agents brought about contradictory results and frequently many aspects of adverse effects, such as infections, immunogenicity, malignancies and so on. In this study, we tried local administration of tumor necrosis factor α antisense oligonucleotide and evaluated the treatment effects on pulmonary fibrosis in bleomycin-induced pulmonary fibrosis mouse model. Flow cytometry for Tregs, RT-PCR for crucial gene expression, western blotting for crucial protein products, immunofluorescent analysis for Th2 cells and myofibroblasts, as well as histology analysis for pathological examination was used. By local administration of tumor necrosis factor α antisense oligonucleotide, we investigated that tumor necrosis factor α expression in epithelial cells was significantly inhibited and extracellular matrix overexpression was dramatically reduced. These treatment effects were associated with the induced regulatory T cells, the reduced TH 2 cells and the generally decreased TH 2-type cytokines expression. Systemic immunosuppression was not triggered by local antisense oligonucleotide administration as the proportion of regulatory T cells in blood, thymus or spleen was not affected. These findings demonstrate that local administration of tumor necrosis factor α antisense oligonucleotide contributes to anti-fibrotic action via sustained up-regulated level of regulatory T cells, which inhibits TH 2-biased responses, pro-fibrotic mediators production and ECM deposition with no systemic immunosupression associated with systemically induced regulatory T cells. This article is protected by copyright. All rights reserved.
    The Journal of Gene Medicine 11/2013; 15(11-12). DOI:10.1002/jgm.2750 · 1.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Remodeling in COPD has at least two dimensions: small airway wall thickening and destruction of alveolar walls. The aim of this study was to characterize and assess similarities in alveolar and small airway wall matrix remodeling in chronic COPD models. From this comparative characterization of matrix remodeling we derived and elaborated underlying mechanisms to the matrix changes reported in COPD. Lung tissue sections of chronic models for COPD, either induced by exposure to cigarette smoke, chronic intratracheal LPS instillation or local TNF expression (SPC-TNFα mice), were stained for elastin, collagen and hyaluronan. Furthermore TNFα, MMP2, 9 and 12 mRNA expression was analyzed using qPCR and localized using immunohistochemistry. Both collagen and hyaluronan were increased in alveolar and small airway walls of all three models. Interestingly, elastin contents were differentially affected, with a decrease in both alveolar and airway walls in SPC-TNFα mice. Furthermore TNFα, and MMP2 and 9 mRNA and protein levels were found to be increased in alveolar walls and around airway walls only in SPC-TNFα mice. We show that only SPC-TNFα mice show changes in elastin remodeling which are comparable to what has been observed in COPD patients. This reveals that the SPC-TNFα model is a suitable model to study processes underlying matrix remodeling and in particular elastin breakdown as seen in COPD. Furthermore we indicate a possible role for MMP2 and MMP9 in the breakdown of elastin in airways and alveoli of SPC-TNFα mice.
    AJP Lung Cellular and Molecular Physiology 08/2014; 307(7). DOI:10.1152/ajplung.00116.2014 · 4.04 Impact Factor

Full-text (2 Sources)

Download
29 Downloads
Available from
Jun 1, 2014